Pancreatic Cancer Research

ResearcherFirst Affiliated Hospital of Wenzhou Medical UniversityActive in the last 2 years

Tao Xue

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5109730180. Sources: OpenAlex.

Their work

Papers
3 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
3
Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: 1 paper · 2023: none · 2024: 1 paper

Papers 3

  1. [Retracted] Emodin alleviates gemcitabine resistance in pancreatic cancer by inhibiting MDR1/P‑glycoprotein and MRPs expression. Last author DOI 10.3892/ol.2024.14568↗
  2. The Biocomplex Assembled from Antigen Peptide and Toll-like Receptor Agonist Improved the Immunity against Pancreatic Adenocarcinoma In Vivo. Co-author DOI 10.1155/2022/2965496↗
  3. Emodin alleviates gemcitabine resistance in pancreatic cancer by inhibiting MDR1/P-glycoprotein and MRPs expression. Last author DOI 10.3892/ol.2020.12030↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hongchun Guo · 2 shared papers, 2020–2024 · strength 0.47
  2. Wenming Feng · 1 shared paper, 2022 · strength 0.19
  3. Ge Cui · 1 shared paper, 2022 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.